{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-193957","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.974239+00:00","generated_at":"2026-05-15T01:04:21.822060+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kymera reports Q1 net loss $69.2M; Gilead licenses KT-200 for $45M milestone","bullets":["Net loss $69.2M in Q1 2026, vs $65.6M in Q1 2025; cash $1.55B provides runway into 2029.","Collaboration revenue $34.4M (all from Gilead), up from $22.1M in Q1 2025.","Gilead exercised option to license KT-200 (oral CDK2 degrader), triggering a $45M milestone payment.","KT-621 Phase 2b BROADEN2 (AD) data expected mid-2027; BREADTH (asthma) data late 2027; FDA Fast Track for asthma.","KT-579 Phase 1 healthy volunteer trial ongoing; data expected in 2H26; KT-485/SAR447971 IND complete, clinical entry 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-193957","json":"https://secwatch.observer/filing/0001193125-26-193957.json","markdown":"https://secwatch.observer/filing/0001193125-26-193957.md","text":"https://secwatch.observer/filing/0001193125-26-193957.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526193957/0001193125-26-193957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526193957/kymr-20260430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:04:21.822060+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b87ed59aea2753dc94652c67b9fce61bbff5e80","claim":"Kymera Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"On April 30, 2026, Kymera Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526193957/0001193125-26-193957-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}